Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Department of Health and Human Services
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Later
Posted
11/18/2024
Closes
2027-01-07
Eligibility
Eligibility
Public housing authorities/Indian housing authoritiesCounty governmentsFor profit organizations other than small businessesOthers (see text field entitled "Additional Information on Eligibility" for clarification)Private institutions of higher educationNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationIndependent school districtsSmall businessesCity or township governmentsNative American tribal governments (Federally recognized)State governmentsPublic and State controlled institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationSpecial district governmentsNative American tribal organizations (other than Federally recognized tribal governments)
Program
Funding area
Education - EDHealth - HL
Opportunity #
PAR-25-070
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov